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Abstract 
BACKGROUND: The expression of many inducible genes, involved in cell growth and differentiation as cytokine 
genes are regulated by receptor-activated intracellular signalling pathways, including the c-Jun N-terminal kinase 
(JNK) mitogen-activated protein kinase pathway.  
AIM: We examined the involvement of the JNK signalling pathway in the regulation of the inducible interleukin-6 
(IL-6) and interleukin-18 (IL-18) gene expression at the transcriptional level.  
METHODS: Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated with 
lipopolysaccharide (LPS) and C3 binding glycoprotein (C3bgp) with or without SP600125 and cultured for 6 h. 
After mRNA isolation, a qRT-PCR was performed.  
RESULTS: Regarding IL-6 and IL-18 mRNA expression, donors were divided into two groups of high and low 
responders. SP600125 inhibited significantly IL-6 mRNA transcription in the high responder group and did not 
influence the transcription level in the low responder group. Concerning IL-18 mRNA, we detect the significant 
effect of SP600125 on the inducible mRNA in high responder group upon C3bgp stimulation.  
CONCLUSION: JNK transduction pathway is involved in the production of IL-6 mRNA, after LPS and C3bgp 
stimulation. We suggest that the inhibition of JNK may be beneficial only for higher responding patients during the 
treatment of inflammatory and autoimmune diseases. 
 
 
 
 
Introduction 
 
The expression of many inducible genes, 
involved in cell growth and differentiation as cytokine 
genes are regulated by a receptor-activated 
intracellular signalling pathways including c-Jun N-
terminal kinase (JNK) mitogen-activated protein 
kinase (MAPK) pathway. JNK is a serine-threonine 
protein kinase that by phosphorylation activates c-Jun, 
a part of the transcription factor AP-1 [1]. Many target 
genes regulating the cell cycle, apoptosis and cell 
survival with AP-1 binding sites are regulated by JNK 
transduction pathway [2]. In immune cells, JNK 
regulates the transcription of a lot of inducible genes, 
including inflammatory cytokine genes [3]. More 
precisely, JNK is involved in the regulation of TNF-α, 
IL-12p40, IL-10 and IL-23 as is shown by previous 
studies of our laboratory [4], [5], [6]. 
Interleukin-6 (IL-6) is a part of the 
inflammatory response initiated by recognition of 
antigens referred to as pathogen-associated 
molecular pattern (PAMP) molecules to the pattern 
recognition receptors (PRR) expressed by immune 
cells. IL-6 is a proinflammatory and immunoregulatory 
cytokine with hormone-like activity – it is involved in 
immune regulation, inflammation, and oncogenesis 
[7]. During acute – phase inflammatory response liver 
cells secrete CRP, serum amyloid A, complement 
proteins and fibrinogen in response to IL-6 stimulation 
[8]. IL-6 also plays a key role in the humoral immune 
response by stimulation of proliferation of activated B 
cells and antibody production [7]. IL-6 induces the 
development of Th17 cells from naive T cells together 
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with TGF-β. Dysregulation and overproduction of IL-6 
are connected to the development of autoimmune 
diseases such as multiple sclerosis (MS) and 
rheumatoid arthritis (RA), in which Th17 cells are 
suspected as the major cause of the diseases [9]. 
Although many somatic cells and cells of the immune 
system produce IL-6 the major source of this cytokine 
are the activated monocytes/macrophages. IL-6 
expression and transducing IL-6 receptor system are 
well understood [10]. Human IL-6 is synthesised as a 
protein containing up to 212 amino acids, including a 
28-amino-acid signal peptide. The core protein is 20 
kDa and glycosylation accounts for the size of 21 – 26 
kDa of natural IL-6 [8]. 
Interleukin-18 (IL-18) is also a pro-
inflammatory cytokine, but it is included in Th1 
polarisation. It’s inducible gene expression after 
recognition of PAMPs by PRR lead to the synthesis of 
an inactive protein (pro – IL-18). Pro – IL-18 (24 kDa) 
is converted into biologically active IL-18 (17.2 kDa) 
by another activation pathway in inflammasome 
complexes through caspase 1-mediated cleavage 
[11], [12]. IL-18 is involved in the development of 
successful Th1 cell-mediated and antitumor immune 
response through its ability to induce IFN-γ secretion 
[13]. Unlike IL-6, the mechanisms regulating IL-18 
gene expression and processing remains unclear. 
In this regard, our study was designed to 
investigate the involvement of the JNK transduction 
pathway in the regulation of the expression of IL-6 and 
IL-18 mRNA and identify the anthrapyrazolone 
inhibitor as a novel potential regulator of LPS-induced 
cytokine production in human blood mononuclear 
cells. 
 
 
Methods 
 
PBMC isolation 
With the approval of the local ethics board, 
blood samples were taken from 18 healthy donors 30-
40-year olds 9 male and 9 females. Informed consent 
was obtained from each participant. The peripheral 
venous blood (10 ml) was collected in sterile tubes 
with ethylenediaminetetraacetic acid (EDTA). 
Peripheral blood mononuclear cells (PBMC) were 
isolated by Histopaque-1077 (Sigma-Aldrich-Merck, 
Darmstadt, Germany) density gradient centrifugation. 
The interface containing PBMC was harvested and 
washed twice with cold RPMI-1640 medium. 
 
Cell cultures and stimulation 
PBMC (1 x 10
6
 cells/ml) cultures were carried 
out in RPMI-1640 (Sigma-Aldrich-Merck, Darmstadt, 
Germany) supplemented with: 10% FBS, 100 U/ml 
penicillin, 100 µg/ml gentamycin and 0.3 mg/ml L-
glutamine. The cells were stimulated with: 30 µg /ml 
C3 binding glycoprotein (C3bgp) isolated as described 
previously [14] or 1 µg/ml Lipopolysaccharide (LPS) 
from Escherichia coli serotype 026: B6 (Sigma-
Aldrich-Merck, Darmstadt, Germany). The 
concentrations of the stimuli used were determined, 
according to Stanilova et al., [15] and Takahashi et al., 
[16]. As shown by our previous study of inducible 
cytokine gene expression transcripts, the maximum 
mRNA quantities were reached after 6 h of stimulation 
and were independent of stimuli used [5]. Therefore, 
PBMC cultures were incubated at 37°C for 6 h. After 
incubation, the cultures were centrifuged at 1800 rpm 
for 10 min. The cell pellet was separated, and the 
RNA was isolated. 
 
Inhibition of JNK MAPK pathway 
One hour before the stimuli addition, some of 
PBMC cultures were pre-treated with an inhibitor of 
JNK kinase. For inhibition of c-jun N-terminal kinase, 
we used the selective anthrapyrazolone inhibitor 
SP600125 (Sigma-Aldrich-Merck, Darmstadt, 
Germany). It competitively inhibits JNK 1, 2 and 3 with 
> 20-fold selectivity vs the wide range of kinases 
according to Bennett et al., [1]. SP600125 is dissolved 
in 100% dimethylsulfoxide (DMSO) (Sigma-Aldrich-
Merck, Darmstadt, Germany), and the final 
concentration of JNK inhibitor in cell cultures is 20 µM. 
Non-stimulated cell cultures were used as controls. 
Therefore, our experiment included the following 
PBMC cultures: non-stimulated, stimulated with LPS, 
stimulated with LPS and pre-treated with SP600125, 
stimulated with C3bgp, stimulated with C3bgp and 
pre-treated with SP600125. 
 
RNA extraction and reverse transcription 
Total RNA from cell culture pellet was isolated 
using innuPREP blood RNA isolation kit AJ 
Roboscreen (Leipzig; Germany) with the additional 
step of treatment with DNase I to remove traces of 
genomic DNA. The total RNA was quantified by 
spectrophotometrical analysis. Synthesis of cDNA 
was performed manually according to the 
manufacturer’s instructions with the High-Capacity 
cDNA Archive kit (Applied Biosystems, Foster City, 
CA) that uses random primers and MutliScribe TM 
MuLV reverse transcriptase enzyme. Incubation 
conditions for reverse transcription were 10 min at 
25°C followed by 2 h at 37°C and was performed on a 
GeneAmp PCR System 9700 (Applied Biosystems). 
 
Quantitative real-time polymerase chain 
 reaction 
Quantitative real-time polymerase chain 
reaction (qRT-PCR) was performed on a 7500 Real-
Time PCR System (Applied Biosystems). The qRT-
PCR primers and probes were purchased from 
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Primerdesign, UK and Termoscientific as predesigned 
inventoried assay reagents. The following validated 
PCR primers, and TaqMan MGB probes (6FAM-
labeled) were used: IL-6 (assay ID: Hs00985639_m1) 
and for IL-18 mRNA (AX-7948-00-0200). As 
endogenous controls were used eukaryotic 18S 
ribosomal RNA (Hs999999_s1) and β2 microglobulin 
(Hs00187842_m1). An aliquot of 5 µl of the RT 
reaction was amplified in duplicate in a final volume of 
20 µl using a TaqMan Universal PCR Master Mix and 
Gene Expression Assay mix, containing specific 
forward and reverse primers and labelled probes for 
target genes and endogenous controls (Applied 
Biosystems). The thermocycling conditions were: 
initial 10 min incubation at 95°C followed by 40 cycles 
of denaturation for 15 s at 95°C and 
annealing/extension for 1 min at 60°C. PCR data were 
collected with Sequence Detection System (SDS) 
software, version 2.3.  
Relative quantitative evaluation of cytokine 
mRNAs was performed by the comparative ΔΔCt 
method. The mean ΔCt obtained in nonstimulated 
controls for each cytokine mRNA was used as a 
calibrator, after normalisation to the average of 
endogenous controls 18S rRNA and β2 microglobulin. 
The results are calculated as an n-fold difference 
relative to the calibrator (RQ=2
-ΔΔCt
).  
 
Statistical analysis 
The data were presented as a 
mean±standard error. One-way ANOVA test was used 
to compare the mean values between all stimuli used, 
followed by post hoc Fisher LSD test to analyse the 
effect of JNK inhibition on LPS or C3bgp induced 
gene expression. Differences were considered 
significant when the p values were < 0.05. 
 
 
Results 
 
IL-6 mRNA expression 
Results presented in Figure 1, showed that 
the transcription of IL-6 mRNA was upregulated after 
stimulation with both LPS and C3bgp. Moreover, the 
healthy donors were divided into two groups – 
individuals with high (RQ > 200) (6 healthy donors) 
and with low (RQ ≤ 200) (12 donors) levels of the 
inducible IL-6 mRNA. In the high responder group, the 
level of mRNA expression in stimulated cultures RQ 
value varied between 219-2387 for LPS and 394-4728 
for C3bgp stimulation. The gene expression was 
significantly affected by a used stimulus in high 
responder group (F = 3.68; df = 3; p = 0.029) in 
contrast to low responder group (F = 1.16; df = 3; p = 
0.35). In the low responder group, the RQ value is 11-
120 for LPS and 13-165 for C3bgp, respectively. We 
found statistically significant inhibition of IL-6 gene 
transcription in cells pretreated with SP600125 
compared to cultures without JNK inhibitor in high 
responder group – LPS vs. LPS + SP600125 p = 
0.014; C3bgp vs. C3bgp + SP600125 p = 0.014 
(Fisher LSD test). In the same experimental condition, 
we did not detect the inhibitory effect of SP600125 on 
the IL-6 gene transcription in the low responder group. 
 
Figure 1: Levels of IL-6 mRNA transcription in PBMC of 18 healthy 
donors after stimulation with 1 μg/ml LPS and 30 μg/ml C3bgp, with 
or without 20 μM JNK inhibitor SP600125. The results are 
presented on a logarithmic scale. The cells were harvested at 6 h 
after stimulation. After mRNA isolation, a qRT-PCR was performed, 
and the results were calculated as an n-fold difference relative to 
calibrator RQ = 2
-∆∆Ct
. The results are presented as mean ± 
standard error; *p < 0.05 for stimulus vs stimulus + SP600125 
 
IL-18 mRNA expression 
The levels of the inducible IL-18 mRNA were 
significantly lower (more than 100-fold) than those of 
IL-6 mRNA after stimulation with LPS and C3bgp. 
Regarding IL-18 mRNA expression individuals were 
also subdivided into two groups: high responders (8 
healthy donors) (RQ between 1.201-1.979 for LPS 
and 1.324-3.249 for C3bgp) and low responders (10 
donors) (RQ varied between 0.720-1.147 for LPS and 
0.454-0.882 for C3bgp), Figure 2.  
 
Figure 2: Levels of IL-18 mRNA transcription in PBMC of 18 healthy 
donors after stimulation with 1 μg/ml LPS and 30 μg/ml C3bgp, with 
or without 20 μM JNK inhibitor SP600125. The cells were harvested 
at 6 h after stimulation. After mRNA isolation, a qRT-PCR was 
performed, and the results were calculated as an n-fold difference 
relative to calibrator RQ = 2
-∆∆Ct
. The results are presented as mean 
± standard error; *p < 0.05 for stimulus vs stimulus + SP600125 
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The gene expression of IL-18 was also 
significantly affected by a used stimulus in high 
responder group (F = 3.21; df = 3; p = 0.039) in 
contrast to low responder group (F = 0.89; df = 3; p = 
0.46). JNK inhibition significantly decreases C3bgp-
induced IL-18 gene expression (C3bgp vs. C3bgp + 
SP600125 p = 0.035, Fisher LSD test) in contrast to 
LPS-induced gene expression (LPS vs. LPS + 
SP600125; p = 0.43) in high responder group. Also, 
upregulation of IL-18 gene expression was 
significantly higher after stimulation with C3bgp 
compared to LPS (p = 0.04).  
 
 
Discussion 
 
To investigate the involvement of JNK MAPK 
in the inducible IL-6 and IL-18 gene expression, we 
used a small selective inhibitor of JNK transduction 
pathway SP600125. The effect of JNK inhibition on 
the IL-6 and IL-18 mRNA expression we determined 
in an experimental model of LPS and C3bgp-
stimulated human PBMC pretreated with inhibitor. Cell 
cultures were harvested on 6 h, and steady-state 
mRNA of IL-6 and IL-18 gene was evaluated by qRT-
PCR.  
We found that healthy donors were divided 
into two groups in terms of mRNA expression of both 
IL-6 and IL-18 genes-individuals with high mRNA 
expression (high responders) and those with low 
mRNA expression (low responders) of the target 
genes. In most cases, the same donors showed high 
or low IL-6 and IL-18 mRNA expression. The 
observed level of expression was distinct between two 
studied groups, showing principal differences of 
individual response in the regulation of IL-6 and IL-18 
expression. Our experiments revealed that value for 
IL-6 after LPS and C3bgp stimulation varied between 
individuals more than a 10-fold range. This variability 
is much greater than would be expected due to 
technical reasons. It is obvious that mechanisms 
determining this variability of induced proinflammatory 
cytokine production should be searched elsewhere, 
probably in the individual genetic background and 
regulation of gene expression as well. Other authors 
also have a similar observation on the inter-individual 
variability in proinflammatory cytokine response, 
especially in response to LPS [17], [18]. Indeed, in 
their study Wurfel et al., discovered 80 genes that 
were differentially expressed in LPS-low and LPS-high 
healthy responders in the presence of LPS and 21 
genes in the absence of LPS [19]. 
In this study for the first time, we showed that 
JNK inhibitor SP600125 selectively mediated its effect 
in PBMC from healthy individuals – SP600125 
downregulated IL-6 gene expression in high 
responder group and did not affect the expression of 
this gene in the low responder group. Other 
researchers did not divide its donors depending on the 
magnitude of IL-6 expression and reported that 
inhibition of JNK reduced IL-6 expression in a different 
type of human cells on the protein level [20], [21] IL-6 
expression is tightly regulated transcriptionally by 
several transcription factors. NF-kB and AP-1 are 
included between the major transcription factors 
responsible for IL-6 gene regulation [22]. Therefore, 
the downregulation of IL-6 gene expression by JNK 
inhibitor in high responder group is not an unexpected 
result. On the contrary, the lack of inhibitory effect of 
SP600125 on low responders indicates that in these 
individuals, the JNK transduction pathway may not be 
involved in inducible IL-6 gene expression. Additional 
experiments with inhibition of ERK and p38 is 
necessary to clarify whether these MAP kinases are 
involved in the regulation of IL-6 production in the low 
responder group. 
At present, it is known that IL-18 mediated 
Th1 type of the immune response, because of its 
property to induce IFN-  secretion from activated T 
cells and NK cells [13]. There is evidence that 
treatment with IL-18 has significant antitumor action 
due to enhanced cell-mediated immune response 
[11]. Also, IL-18 administration in mice inoculated with 
tumour cell line stimulated IFN-  production and IL-12 
independent Th1 cell-mediated antitumor immune 
response [23]. Our study indicated that SP600125 
downregulated significantly IL-18 mRNA expression in 
PBMC after C3bgp, but not after LPS stimulation. 
There are few studies about JNK inhibition and its 
effect on IL-18 secretion. Similar results regarding the 
absence of an inhibitory effect of SP600125 after LPS 
stimulation was reported in primary human 
keratinocytes activated by β-defensins in the work of 
Niyonsaba et al., [24]. However, our results support 
the study of Miyauchi et al., reporting that JNK 
inhibition by SP600125 in human tubular epithelial cell 
from type 2 diabetic subjects significantly suppressed 
TGF-β-induced IL-18 expression [25] or Wang et al., 
showing that SP600125 inhibited IL-18 mRNA 
expression in murine peritoneal macrophages after 
heat shock response [26].  
Currently, it is widely accepted that IL-6, 
together with TGF-β, induced the development of 
normal Th17 cells, whereas the additive presence of 
IL-23 and IL-1 lead to the development of pathological 
Th17 subset [27]. The pathological Th17 cells are 
recognised as essential cells responsible for the 
development of chronic inflammatory conditions and 
autoimmune diseases. The upregulated prolonged 
synthesis of IL-6, both genetically and epigenetically 
determined, has a significant role in the development 
of many diseases, including autoimmune and cancers. 
Dysregulated IL-6 production and subsequently, the 
presence of pathologic CD4 + Th17 cells were 
described in rheumatoid arthritis, multiple sclerosis, 
myeloma, systemic lupus erythematosus and others 
[9], [22]. Because of the pathologic role of IL-6 in the 
therapy of these diseases is used anti-IL-6R 
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monoclonal antibody tocilizumab that block IL-6 
mediated signal transduction. There was an 
observation that tocilizumab alleviated diseases 
symptoms, but also several side effects are described, 
including hypercholesterolemia, acute pyelonephritis, 
inflammation of the upper respiratory system and 
parotid glands [28]. During immune response 
development of the Th1 type of the response 
suppressed the development of the Th17 cells by the 
secretion of IFN- [29]. Therefore, in the context of an 
autoimmune response downregulation of IL-6 
expression by the SP600125 application may provide 
a desirable effect in the treatment of these diseases in 
high responding patients.  
The results and conclusions in this article are 
based on studies conducted within 18 healthy donors 
and PBMC isolated from them.  
In conclusion, the JNK MAPK transduction 
pathway is selectively involved in the production of IL-
6 mRNA, after LPS and C3bgp stimulation, and IL-18 
mRNA after C3bgp stimulation from PBMC isolated 
from higher responding individuals. We suggest that 
the inhibition of JNK may be beneficial only for higher 
responding patients during the treatment of 
inflammatory and autoimmune diseases mediated by 
the unbalanced Th1/Th17 type of immune response. 
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